View Cart  

Amphastar Slow to Report SAEs, Form 483 States

Amphastar Pharmaceuticals is slow to notify the FDA about complaints of serious and/or unexpected adverse events associated with its various generic drug products, a Form 483 states.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $135.00